Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Blood Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Chronic Myeloid Leukemia (CML), one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$13.6 Billion by the ... Read More
-
Ovarian Cancer Diagnostics
... at a CAGR of 3.5% over the analysis period 2024-2030. Epithelial Tumor, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Blood Cancer Diagnostics
... at a CAGR of 5.4% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$8.4 Billion by the end of the ... Read More
-
Breast Cancer Core Needle Biopsy
... Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Ultrasound-based Breast Biopsy, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$569.3 ... Read More
-
Breast Cancer Diagnostics
... at a CAGR of 6.4% over the analysis period 2024-2030. Imaging Techniques, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$3.0 Billion by the end of ... Read More
-
Castrate-Resistant Prostate Cancer
... at a CAGR of 7.7% over the analysis period 2024-2030. Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$10.2 Billion by the end of ... Read More
-
Estrogen Receptor Positive Breast Cancer Treatment
... reach US$30.1 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$11.1 ... Read More
-
Stomach Cancer Treatment
... at a CAGR of 12.1% over the analysis period 2024-2030. Standard Chemotherapy, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.0 Billion by the end of ... Read More
-
Pancreatic Cancer Treatment
... at a CAGR of 11.2% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$1.3 Billion by the end of the ... Read More
-
Cancer Pain Management
... at a CAGR of 3.6% over the analysis period 2024-2030. Acute Pain Type, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$4.1 Billion by the end ... Read More
-
Bladder Cancer Diagnostics
... at a CAGR of 6.9% over the analysis period 2024-2030. Urine Lab Tests, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.2 Billion by the end ... Read More
-
Gastric Cancer Diagnostics
... at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end ... Read More
-
Metastatic Cancer Drugs
... at a CAGR of 6.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$57.8 Billion by the end of the ... Read More
-
Colorectal Cancer Diagnostics
... at a CAGR of 5.3% over the analysis period 2024-2030. Adenocarcinoma, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Cancer Therapeutics and Biotherapeutics
... 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$64.0 Billion by the ... Read More
-
Thyroid Cancer Diagnostics
... at a CAGR of 3.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$4.0 Billion by the end of the ... Read More
-
Biliary Tract Cancers
... at a CAGR of 3.7% over the analysis period 2024-2030. Intrahepatic Cholangiocarcinoma, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$447.3 Million by the end of ... Read More
-
Clinical Nutrition for Cancer Care
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Oral Nutrition Type, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$3.0 ... Read More
-
Follicular Thyroid Cancer Drugs
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Papillary Carcinoma Type, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$515.5 Million by ... Read More
-
Prostate Cancer Devices
... at a CAGR of 9.8% over the analysis period 2024-2030. Radiation Treatment Devices, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$3.1 Billion by the end ... Read More
-
Esophageal Cancer Drugs
... at a CAGR of 6.1% over the analysis period 2024-2030. Esophageal Squamous-Cell Carcinoma, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$14.8 Billion by the end ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Intraoperative Radiation Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Systems / Accelerators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$22.9 Million by the end ... Read More
-
Next Generation Cancer Diagnostics
... 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by ... Read More
Research Assistance
